4-1BB Antibodies in Oncology Clinical Trials: A Review
4-1BB is a transmembrane glycoprotein found on T lymphocytes, and signaling through 4-1BB activates and differentiates CD3+ and CD8+ T cells. The ability of 4-1BB to stimulate cytotoxic T-cell responses makes it a promising target for therapeutic cancer immunotherapy development. 4-1BB antibodies ha...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2025-03-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-24-30 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232635693989888 |
|---|---|
| author | Robin Schwartz Keerti Vajrala Gerald S. Falchook |
| author_facet | Robin Schwartz Keerti Vajrala Gerald S. Falchook |
| author_sort | Robin Schwartz |
| collection | DOAJ |
| description | 4-1BB is a transmembrane glycoprotein found on T lymphocytes, and signaling through 4-1BB activates and differentiates CD3+ and CD8+ T cells. The ability of 4-1BB to stimulate cytotoxic T-cell responses makes it a promising target for therapeutic cancer immunotherapy development. 4-1BB antibodies have shown promising antitumor activity in preclinical studies and clinical trials. Common side effects include transaminase elevation, cytopenias, fatigue, and nausea. This clinical review summarizes past and current 4-1BB antibodies in oncology clinical trials. |
| format | Article |
| id | doaj-art-1e202b1fda6e4642802b04bc0bdd1c49 |
| institution | OA Journals |
| issn | 2666-2345 2590-017X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj-art-1e202b1fda6e4642802b04bc0bdd1c492025-08-20T02:03:07ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2025-03-018212113110.36401/JIPO-24-30i2590-017X-8-2-1214-1BB Antibodies in Oncology Clinical Trials: A ReviewRobin Schwartz0Keerti Vajrala1Gerald S. Falchook2https://orcid.org/0000-0001-9165-21911 Sarah Cannon Research Institute at HealthONE, Denver, CO, USA2 Kansas City University College of Osteopathic Medicine, Kansas City, MO, USA1 Sarah Cannon Research Institute at HealthONE, Denver, CO, USA4-1BB is a transmembrane glycoprotein found on T lymphocytes, and signaling through 4-1BB activates and differentiates CD3+ and CD8+ T cells. The ability of 4-1BB to stimulate cytotoxic T-cell responses makes it a promising target for therapeutic cancer immunotherapy development. 4-1BB antibodies have shown promising antitumor activity in preclinical studies and clinical trials. Common side effects include transaminase elevation, cytopenias, fatigue, and nausea. This clinical review summarizes past and current 4-1BB antibodies in oncology clinical trials.https://jipo.org/doi/pdf/10.36401/JIPO-24-304-1bbcd137clinical trialimmunotherapy |
| spellingShingle | Robin Schwartz Keerti Vajrala Gerald S. Falchook 4-1BB Antibodies in Oncology Clinical Trials: A Review Journal of Immunotherapy and Precision Oncology 4-1bb cd137 clinical trial immunotherapy |
| title | 4-1BB Antibodies in Oncology Clinical Trials: A Review |
| title_full | 4-1BB Antibodies in Oncology Clinical Trials: A Review |
| title_fullStr | 4-1BB Antibodies in Oncology Clinical Trials: A Review |
| title_full_unstemmed | 4-1BB Antibodies in Oncology Clinical Trials: A Review |
| title_short | 4-1BB Antibodies in Oncology Clinical Trials: A Review |
| title_sort | 4 1bb antibodies in oncology clinical trials a review |
| topic | 4-1bb cd137 clinical trial immunotherapy |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-24-30 |
| work_keys_str_mv | AT robinschwartz 41bbantibodiesinoncologyclinicaltrialsareview AT keertivajrala 41bbantibodiesinoncologyclinicaltrialsareview AT geraldsfalchook 41bbantibodiesinoncologyclinicaltrialsareview |